Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development

Table 1 Clinical characteristics of PLWHA in the study population (n = 4918)

Clinical characteristic	Number (Percent) of Individuals
Gender
Male	4016 (81.7%)
Female	902 (18.3%)
Age (years) at Start of Anti-retroviral Therapy
Under 30	697 (14.1%)
30–39	1932 (39.3%)
40–49	1519 (30.9%)
50 or more	770 (15.7%)
Nadir CD4 Level
Less than 50	1402 (28.5%)
50–99	686 (13.9%)
100–199	1430 (29.1%)
200 or more	1400 (28.5%)
Baseline Viral Load
(Log base 10)^a	4.95 (4.40–5.00)
Intravenous Drug Use
Yes	1766 (35.9%)
No	3152 (64.1%)
ADM Status
Yes	251 (5.1%)
No	4667 (94.9%)
Hepatitis C Status
Positive	2014 (41.0%)
Negative	2110 (42.9%)
Unknown	794 (16.1%)
Use of HAART^b
Yes	4275 (86.9%)
No	643 (13.1%)
Start of Antiretroviral Therapy^c
Early-HAART era (before 2000)	2093 (42.6%)
Late-HAART era (2000 and after)	2825 (57.4%)

^aMedian and Interquartile Range (IQR)
^bAll individuals were treated with antiretroviral therapy (monotherapy, dual therapy or triple therapy); selected individuals were treated with HAART (triple therapy) according to guidelines at time of treatment
^cThe year cut-point was utilized to represent use of more efficient HAART starting in the year 2000

ISSN: 1471-2407